Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 'Treatable Traits' approach unlock better care for all airway diseases?

NCT ID NCT05976919

Knowledge-focused Sponsor: University of Leeds Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study looks at people with different chronic airway diseases—like COPD, asthma, and cystic fibrosis—to compare lung function, exercise capacity, physical activity, and body composition. The goal is to identify 'treatable traits' that could help personalize treatment for each person. Researchers will measure step counts, lung function, and body composition in 80 adults aged 18-65 with or without airway disease. The findings may lead to more tailored care that improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pulmonary function testing, exercise testing, physical activity monitoring, and body composition assessment
What this could lead to
If successful, this could help tailor treatments to individual patients with different airway diseases, improving quality of life and physical activity.
What could go wrong
This is an observational study with a small sample size, so findings may not apply to all patients. It does not test a treatment, so direct benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

80 people

The number who actually took part.

Started

Oct 2023

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chronic obstructive airways disease

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prior diagnosis of airways disease in accordance with European Respiratory Society guidelines. * Non / ex-smokers (packs recorded as cigarettes per day / years smoked). * Male or female aged 18-65 years * Ability to provide written informed consent. * Full comprehension of spoken and written English language. * Cystic Fibrosis patients on triple CFTR modulators (90% cohort) * Cystic Fibrosis patients on no CFTR modulators * Healthy controls - entirely asymptomatic, no prior history of inhaler medication use and free from respiratory disease. Exclusion Criteria: * Severe exacerbation requiring hospital admission or oral corticosteroids (OCS) in the past two months. * Absolute or relative contraindications to cardio-pulmonary exercise testing or submaximal exercise testing. * Absolute or relative contraindications to pulmonary function testing . * Absolute or relative contraindications to dual energy x-ray (DEXA) scanning (i.e., pregnancy, recent contrast media administration or subject weight). * Non-ambulant or musculoskeletal impairment that may affect activities of daily living or maximal exercise testing. * Significant cognitive impairment (i.e., unable to provide written informed consent or safely / successfully perform tests). * Currently receiving oxygen therapy. * Inability to consent. * Burkholderia Cepacia Complex, mycobacterium tuberculosis or mycobacterium abseccus infection. * Lung transplantation * Diagnosis of cardiovascular disease. * Abnormal blood screening (anaemia, moderate / severe renal failure etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Airway disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Airway disease

Contacts and locations

Locations

  • University of Leeds

    Leeds, Leeds, LS2 9JT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.